Press releases

Clinical presentations to include 12-month outcomes data from EVOLVE trial and results of the REPRISE I trial.

Advanced pacemaker platform designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

Clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions.

REPRISE I Trial Results to be Presented at EuroPCR 2012

Fesults “demonstrate continued progress towards improving our future growth profile and in executing our strategic plan," said CEO Hank Kucheman.

Device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 2012 on April 19. Learn how to tune in or watch the replay.

Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.

CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma.

HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients.

Results were presented at the American College of Cardiology Annual Scientific Sessions.

Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012.

Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract.

Data to include two-year results from the PLATINUM Workhorse clinical trial, with follow-up data on PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent.

Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma.

Radiofrequency ablation catheter designed to treat a variety of arrhythmias.

Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest.

Five-year contract extends the existing commercial agreement, promotes continued investments in laser and fiber product development for urologic applications.

Next-generation coronary stent employs innovative alloy designed to improve acute performance.

TELIGEN family of ICDs, designed to treat sudden cardiac death, are the smallest and thinnest high-energy devices available in China.

ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.

Moody's Investors Service has upgraded the Company's corporate credit rating to an investment grade rating, Baa3, with a stable outlook.

TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions.

Studies published in peer-reviewed medical journals

New device offers excellent flexibility and large size for acquiring tissue samples.

“We continue to make progress with new product introductions, cost-saving initiatives and a strengthened presence in emerging markets," said CEO Hank Kucheman.

Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries.

NICE report supports safety and effectiveness of Alair® System

Johnson and Johnson's patents found invalid

Boston Scientific will webcast its conference call with financial results for Q4 and full year ended December 31, 2011. Learn how to tune in or watch the replay.

Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting

CMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma.

Boston Scientific's third new peripheral balloon catheter introduced in 2011 strengthens Company's position as a global leader in peripheral angioplasty balloons.

Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...

Extended ICD/CRT-D program offers warranties up to 10 years

New family of cardiac devices offers excellent longevity and industry's longest warranty.

Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.

Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke.

Positive results from COBRA trial presented at TCT

EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer.

Carotid WALLSTENT shown to be a safe alternative to carotid endarterectomy (CEA) in patients with carotid artery stenosis who are at increased risk for surgery.

PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year.

Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent.

Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy.

Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent.

Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online

“Boston Scientific’s POWER strategy is the right top priority for the entire leadership team," said CEO Hank Kucheman.

BWallFlex study includes patients with bile duct strictures associated with post liver transplant anastomosis, prior abdominal surgery and chronic pancreatitis.